Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Incyte (INCY) PT Raised to $109 at BofA Securities
October 28, 2025 10:31 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Incyte (NASDAQ: INCY) to $109.00 (from $104.00) while maintaining a Buy rating.
The analyst comments "Incyte (INCY) reported 3Q revenues for Jakafi of $791mn (+2% q/q, ours: $774mn, cons: $773mn), Opzelura of $188mn (+6% q/q, our:... More
